Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

NCT05176080 | Terminated Phase 1

• 1 other identifier: BC-IIT-FMTN-SHR6390-ET
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.

Conditions

Metastatic Breast Cancer

Outcome Measures

Primary Outcomes (2)

• RP2D in phase Ib

  Recommended phase II dose (PR2D) in phase Ib

  Up to 4 weeks

• ORR in phase II

  Objective response rate (ORR) by investigator in phase II

  up to 2 years

Secondary Outcomes (4)

• ORR in phase Ib

  up to 2 years

• PFS in phase Ib

  up to 2 years

• PFS in phase II

  up to 2 years

• AE

  up to 2 years

Study Arms (1)

Treatment group

EXPERIMENTAL

Famitinib Plus SHR6390 and Endocrine therapy

Drug: Famitinib; Drug: SHR6390; Drug: Fulvestrant

Interventions

Famitinib DRUG

Famitinib orally, daily or every other day

Treatment group

SHR6390 DRUG

SHR6390 orally, daily for 3 weeks followed by 1 week off

Also known as: Dalpiciclib

Treatment group

Fulvestrant DRUG

Fulvestrant

Treatment group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Local recurrent or metastatic breast cancer unsuitable for chemotherapy, confirmed histologically.
• HR-positive, HER2- negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
• Ib: Patients who received no more than 2 line of chemotherapy in advanced setting were recruited; II: Patients who had not received any chemotherapy and no more than 1 line of endocrine therapy.
• years old.
• Eastern Cooperative Oncology Group (ECOG) performance status 0～1.
• life expectancy is not less than 12 weeks.
• at least one measurable lesion according to RECIST 1.1.
• Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L, Platelets ≥90×10\^9/L, Hemoglobin ≥ 90 g/L; Total bilirubin≤1.5 upper limit of normal (ULN)；Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN (ALT and AST≤5×ULN if liver metastasis); blood urea nitrogen (BUN) and Creatinine (Cr)≤1.5×ULN
• Left ventricular ejection fraction (LVEF) ≥ 50% and QTc≤470 ms

You may not qualify if:

• Patients who received Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine kinase inhibitors (TKI); II: Patients who received fulvestrant, everolimus or cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor;
• Ib: Patients who had symptomatic brain metastasis; II: Patients who had brain metastasis;
• Patients unsuitable for endocrine therapy;
• Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.
• Participated in other drug clinical trials within 4 weeks before admission
• Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
• Active human immunodeficiency virus (HIV), hepatitis B or hepatitis C;
• Has suffered from any heart disease
• Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
• According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
• Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever（\> 38.5 ℃） of unknown origin occurs during the screening period/before the first administration.
• Researchers believe that patients are unsuitable for any other situation in this study.

Sponsors & Collaborators

• Henan Cancer Hospital: lead

Study Sites (1)

Henan Cancer Hospital

Zhengzhou, Henan, China

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

famitinib; dalpiciclib; Fulvestrant

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Estradiol; Estrenes; Estranes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Estradiol Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

• Min Yan

  Henan Cancer Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 18, 2021
• First Posted: January 4, 2022
• Study Start: December 8, 2021
• Primary Completion: July 3, 2024
• Study Completion: July 3, 2024
• Last Updated: December 17, 2024

Record last verified: 2024-10

Locations

CN (1)